MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3900
0.0000
0.00%
Opening 10:59 05/26 EDT
OPEN
0.3900
PREV CLOSE
0.3900
HIGH
0.3962
LOW
0.3900
VOLUME
33.56K
TURNOVER
3.77K
52 WEEK HIGH
1.840
52 WEEK LOW
0.3401
MARKET CAP
23.83M
P/E (TTM)
-0.9542
1D
5D
1M
3M
1Y
5Y
Recap: Cellectar Biosciences Q1 Earnings
Cellectar Biosciences (NASDAQ:CLRB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Cellectar Biosciences reported in-line EPS of $-0.1 versus an estimate of $-0.1.
Benzinga · 05/10 14:53
BRIEF-Cellectar Reports Financial Results For First Quarter 2022
reuters.com · 05/10 12:57
Cellectar Biosciences GAAP EPS of -$0.10 in-line
Cellectar Biosciences press release (NASDAQ:CLRB): Q1 GAAP EPS of -$0.10 in-line. As of March 31, 2022, the company had cash and cash equivalents of $30.6 million, compared to $35.7 million
Seekingalpha · 05/10 12:52
Cellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patients
Cellectar Biosciences (NASDAQ:CLRB) on Tuesday said an independent committee recommended that the company continue its phase 2b study of its cancer therapy iopofosine to treat Waldenstrom’s macroglobulinemia (WM), a rare
Seekingalpha · 04/26 13:16
Cellectar Biosciences Announces DMC Review Of Pivotal Trial Of Iopofosine In Waldenstrom's Macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced
Benzinga · 04/26 12:12
BRIEF-Cellectar Biosciences Reports Positive DMC Review of Trial of Iopofosine
reuters.com · 04/26 12:09
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
Unanimous Agreement on Successful Achievement of Futility/Efficacy AssessmentFLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develo...
GlobeNewswire · 04/26 12:00
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
Benzinga · 04/18 09:21
More
No Data
Learn about the latest financial forecast of CLRB. Analyze the recent business situations of Cellectar Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLRB stock price target is 5.10 with a high estimate of 10.00 and a low estimate of 2.000.
High10.00
Average5.10
Low2.000
Current 0.3900
EPS
Actual
Estimate
-0.09-0.07-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 7.98M
% Owned: 13.07%
Shares Outstanding: 61.10M
TypeInstitutionsShares
Increased
6
1.21M
New
1
60.00K
Decreased
5
633.37K
Sold Out
10
408.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.56%
Pharmaceuticals & Medical Research
+0.67%
Key Executives
Non-Executive Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer
Chad Kolean
Chief Operating Officer
Jarrod Longcor
Vice President/Director of Marketing
Matthew Hagan
Other
David Lasecki
Other
Laurence Reilly
Director
Asher Alban Chanan-Khan
Independent Director
Frederick Driscoll
Independent Director
Stefan Loren
Independent Director
John Neis
No Data
No Data
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.